about
Regulation of osteoblastogenesis and osteoclastogenesis by the other reproductive hormones, Activin and InhibinThe Effect of Teriparatide on Fracture Healing of Osteoporotic Patients: A Meta-Analysis of Randomized Controlled TrialsAre osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL.Basal bone phenotype and increased anabolic responses to intermittent parathyroid hormone in healthy male COX-2 knockout mice.Cord blood-derived macrophage-lineage cells rapidly stimulate osteoblastic maturation in mesenchymal stem cells in a glycoprotein-130 dependent manner.Elevated serum IGF-1 levels synergize PTH action on the skeleton only when the tissue IGF-1 axis is intact.Targeted deletion of a distant transcriptional enhancer of the receptor activator of nuclear factor-kappaB ligand gene reduces bone remodeling and increases bone mass.Molecular basis of parathyroid hormone receptor signaling and trafficking: a family B GPCR paradigm.Recent advances toward the clinical application of PTH (1-34) in fracture healing.Identification of an orally active small-molecule PTHR1 agonist for the treatment of hypoparathyroidism.Tumor expressed PTHrP facilitates prostate cancer-induced osteoblastic lesions.Parathyroid hormone analogues in the treatment of osteoporosis.Use of bone turnover markers in clinical osteoporosis assessment in women: current issues and future options.Use of teriparatide off-label: our experience and review of literature.Parathyroid hormone analogues for fracture healing: protocol for a systematic review and meta-analysis of randomised controlled trials.Osteoclasts, no longer osteoblast slaves.
P2860
Q24633744-082C381D-4601-4979-8FBE-F948B037594AQ27010303-C77EEF35-C7E3-420B-BEA8-58E4AE05B1F6Q34107428-30711E39-4081-4B01-8047-E877B36EB557Q34667102-371A45E5-1EE8-4CF6-AFB2-D98C0859B9C0Q34998618-99B08ABE-F4D2-455C-96A9-ED52C100CFC9Q35054363-463967B0-12F4-4AB5-B89C-423A8FF18063Q36372606-7898C173-85C2-49CF-BFE1-803C90D3417EQ36599592-F8CEC8AE-BE17-4CB0-BEC2-98D27870E40DQ37348655-73563B90-1557-4B27-A9BD-3F7E073BA0C2Q37430684-EE8474FA-02D7-4498-8497-7F2E1C9C0BF5Q37691805-A5192B7B-C15A-4A90-B9FB-84ACB1403CF4Q37900475-832BED70-DE46-4031-8BF4-7BE9661DA694Q37951107-8420FCAF-41D2-4480-92A5-25567D429479Q39455766-7F450219-0DD3-44C8-B53E-B6D7E13FFE4FQ48181470-478E6080-81F8-412D-BA21-5CAE2927CB51Q50304009-CE68473E-9ECA-41AC-A78E-E9AB25EF2C43
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Mechanisms involved in skeletal anabolic therapies.
@ast
Mechanisms involved in skeletal anabolic therapies.
@en
type
label
Mechanisms involved in skeletal anabolic therapies.
@ast
Mechanisms involved in skeletal anabolic therapies.
@en
prefLabel
Mechanisms involved in skeletal anabolic therapies.
@ast
Mechanisms involved in skeletal anabolic therapies.
@en
P2093
P2860
P356
P1476
Mechanisms involved in skeletal anabolic therapies
@en
P2093
P2860
P304
P356
10.1196/ANNALS.1346.043
P407
P577
2006-04-01T00:00:00Z